Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus MYOZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus MYOZYME.
ELFABRIO vs MYOZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA) that hydrolyzes glycogen to glucose in lysosomes. It replaces deficient GAA enzyme activity in patients with Pompe disease.
1 mg/kg intravenously over 2 hours every 2 weeks.
20 mg/kg IV every 2 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
The terminal elimination half-life of alglucosidase alfa is approximately 2.3 hours at steady state. This short half-life necessitates weekly intravenous infusions to maintain therapeutic enzyme levels in target tissues.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Renal elimination is the primary route of clearance for alglucosidase alfa. Following intravenous administration, the drug is cleared via catabolism into small peptides and amino acids, which are then excreted renally. Less than 5% of the administered dose is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy